Nuchal translucency screening and anxiety levels in pregnancy and puerperium

Ultrasound in Obstetrics and Gynecology

Volumn 27, Issue 4, 2006, Pages 357-361

  Muller M A ^a   Bleker, O P ^a   Bonsel, G J ^a   Bilardo, C M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Anxiety; Down syndrome; HADS; Nuchal translucency screening; Ultrasound

Indexed keywords

ADULT; ANXIETY; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; FEMALE; GESTATIONAL AGE; HEALTH SERVICE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; HUMAN EXPERIMENT; MEDICAL INFORMATION; MIDWIFE; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANT WOMAN; PRENATAL CARE; PRENATAL SCREENING; PRIORITY JOURNAL; PUERPERIUM; QUESTIONNAIRE; RELIGIOUS GROUP; SCORING SYSTEM; SPONTANEOUS ABORTION;

ADULT; ANXIETY; CASE-CONTROL STUDIES; DEPRESSION; DOWN SYNDROME; FEMALE; HUMANS; INFANT, NEWBORN; NETHERLANDS; NUCHAL TRANSLUCENCY MEASUREMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT EDUCATION AS TOPIC; PATIENT SELECTION; POSTPARTUM PERIOD; PREGNANCY; PSYCHIATRIC STATUS RATING SCALES; STATISTICS, NONPARAMETRIC;

EID: 33646683845     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.2761     Document Type: Article

References (23)

1. Green JM, Hewison J, Bekker HL, Bryant LD, Cuckle HS. Psychosocial aspects of genetic screening of pregnant women and newborns: a systematic review. Health Technol Assess 2004; 8: 1-138.
2. Marteau TM, Cook R, Kidd J, Michie S, Johnston M, Slack J, Shaw RW. The psychological effects of false positive results in prenatal screening for fetal abnormality: a prospective study. Prenat Diagn 1992; 12: 205-214.
3. Salonen R, Kurki L, Lappalainen M. Experiences of mothers participating in maternal serum screening for Down syndrome. Eur J Hum Genet 1996; 4: 113-119.
4. Kaiser AS, Ferris E, Katz R, Pastuszak A, Llewellyn-Thomas H, Johnson JA, Shaw BF. Psychological responses to prenatal NTS counseling and the uptake of invasive testing in women of advanced maternal age. Patient Educ Courts 2004; 54: 45-53.
5. Weinans MJ, Kooij L, Müller MA, Bilardo KM, van Lith JM, Tymstra T. A comparison of the impact of screen-positive results obtained from ultrasound and biochemical screening for Down syndrome in the first trimester: a pilot study. Prenat Diagn 2004; 24: 347-351.
6. Kaiser AS, Ferris LE, Pastuszak AL, Llewellyn-Thomas H, Johnson JA, Conacher S, Shaw BF. The effects of prenatal group genetic counselling on knowledge, anxiety and decisional conflict: issues for nuchal translucency screening. J Obstet Gynaecol 2002; 22: 246-255.
7. Müller MA, Bleker OP, Bonsel GJ, Bilardo CM. Women's opinion on the offer and use of nuchal translucency screening for Down syndrome. Prenat Diagn 2006; 26: 105-111.
8. Tam WH, Lee DT, Chiu HF, Ma KC, Lee A, Chung TK. A randomised controlled trial of educational counselling on the management of women who have suffered suboptimal outcomes in pregnancy. BJOG 2003; 110: 853-859.
9. Sjostrom H, Langius-Eklof A, Hjertberg R. Well-being and sense of coherence during pregnancy. Acta Obstet Gynecol Scand 2004; 83: 1112-1118.
10. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370.
11. Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van Hemert AM. A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med 1997; 27: 363-370.
12. Graham W, Smith P, Kamal A, Fitzmaurice A, Smith N, Hamilton N. Randomised controlled trial comparing effectiveness of touch screen system with leaflet for providing women with information on prenatal tests. BMJ 2000; 320: 155-160.
13. Quagliarini D, Betti S, Brambati B, Nicolini U. Coping with serum screening for Down syndrome when the result is given as a numeric value. Prenat Diagn 1998; 18: 816-821.
14. Michie S, Smith D, Marteau TM. Prenatal tests: how are women deciding? Prenat Diagn 1999; 19: 743-748.
15. Berne-Fromell K, Josefson G, Kjessler B. Who declines from antenatal serum alpha-fetoprotein screening-and why? Acta Obstet Gynecol Scand 1984; 63: 687-691.
16. Lubin B, Gardener SH, Roth A. Mood and somatic symptoms during pregnancy. Psychosom Med 1975; 37: 136-146.
17. Statham H, Green JM, Kafetsios K. Who worries that something might be wrong with the baby? A prospective study of 1072 pregnant women. Birth 1997; 24: 223-233.
18. Berne-Fromell K, Kjessler B. Anxiety concerning fetal malformations in pregnant women exposed or not exposed to an antenatal serum alpha-fetoprotein screening program. Gynecol Obstet Invest 1984; 17: 36-39.
19. Burton BK, Dillard RG, Clark EN. Maternal serum alpha-fetoprotein screening: the effect of participation on anxiety and attitude toward pregnancy in women with normal results. Am J Obstet Gynecol 1985; 152: 540-543.
20. Georgsson OS, Saltvedt S, Grunewald C, Waldenstrom U. Does fetal screening affect women's worries about the health of their baby? A randomized controlled trial of ultrasound screening for Down syndrome versus routine ultrasound screening. Acta Obstet Gynecol Scand 2004; 83: 634-640.
21. Jorgensen FS. User acceptability of an alpha-fetoprotein screening programme. Dan Med Bull 1995; 42: 100-105.
22. Statham H, Green J. Serum screening for Down syndrome: some women's experiences. BMJ 1993; 307: 174-176.
23. Spencer K. Uptake of prenatal screening for chromosomal anomalies: impact of test results in a previous pregnancy. Prenat Diagn 2002; 22: 1229-1232.